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Abstract
Background: Leber’s hereditary optic neuropathy (LHON) is a mitochondrial disease characterized by visual loss
consequent to optic nerve atrophy. In some cases, LHON is associated with heterogeneous neurological extraocular
manifestations and is referred to as “Leber plus disease”; rarely it is associated with a multiple sclerosis (MS)-like
syndrome known as Harding disease, but no pediatric extraocular acute spinal onset is reported.
Case presentation: We describe the case of a 5-year-old girl carrying the G3460A mtDNA mutation who was
referred to clinical examination for bilateral upper and lower limb weakness with no sign of optic neuropathy.
Spinal cord MRI showed hyperintense signal alterations in T2-weighted and restricted diffusion in DWI sequences in
the anterior portion of the cervical and dorsal spinal cord resembling a spinal cord vascular injury. No association
between this mutation and pediatric spinal cord lesions has previously been reported. Alternative diagnostic
hypotheses, including infective, ischemic and inflammatory disorders, were not substantiated by clinical and
instrumental investigations.
Conclusions: Our case reports a novel pediatric clinical manifestation associated with the m.3460G > A mtDNA
mutation, broadening the clinical spectrum of this disease. Early identification of new cases and monitoring of
carriers beginning in childhood is important to prevent neurological deterioration and preserve long-term function.
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Background
Leber’s hereditary optic neuropathy (LHON) is a mater-
nally inherited genetic disease that occurs due to a mito-
chondrial DNA (mtDNA) mutation that causes central,
bilateral, painless, progressive visual loss due to optic
nerve atrophy, particularly in young adult men [1].
Three disease-causing mutations that affect subunits of
complex I of the mitochondrial respiratory chain
(MTND1: m.3460G > A, MTND4: m.11778G > A, and
MTND6: m.14484 T > C) are responsible for 90% of the
cases. The extraocular manifestations of the disease,
known as “Leber plus disease”, include movement
disorders, mental retardation, seizures, cerebellar ataxia,
and peripheral neuropathy [1]. Other associations, such
as multiple sclerosis (MS)-like syndrome, referred to as
“Harding disease” or “LHON-MS” [2], Leigh-like en-
cephalopathy and MELAS (mitochondrial encephalomy-
opathy, lactic acidosis and stroke-like episodes)/LHON
overlap syndromes, have also been reported [3]. We de-
scribe a 5-year-old girl affected by an acute spinal cord
lesion mimicking a vascular lesion. The patient had a
family history of LHON due to the G3460A mtDNA
mutation.
Case presentation
A 5-year-old girl was admitted to our Emergency De-
partment after an episode of acute interscapular back
pain occurring without trauma and followed by bilateral
upper and lower limb weakness.
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Her family history included 8 Italian members harboring
the same homoplasmic m.3460G > A mtDNA (Table 1,
Fig. 1a). All the family members presented headache
poorly responsive to NSAIDs and, except for the girl and
her mother, visual loss due to optic nerve pathology. The
patient’s medical history was unremarkable.
The patient’s vital signs were normal and stable. At the
neurological examination, her cognitive functions were
normal. There were no cranial nerve lesions. She was
unable to stand and walk and had more severe weakness
in the right lower limb. She also presented weakness in
her upper extremities and difficulties with fine hand
movements, particularly in the right hand. The right pa-
tellar and Achilles tendon reflexes were brisk. The plan-
tar reflex was positive in the right foot. She presented
impaired bladder control. No alterations in touch or
pain sensitivity were present in the trunk and limbs. No
concomitant signs of infection or inflammation were
present, and no such signs had been reported in the pre-
vious weeks. Analyses of CSF pressure, glucose, protein,
cell count, viral PCR, and culture were normal, and oli-
goclonal bands were absent (see timeline of events and
treatment in Fig. 2). The patient underwent a spinal cord
MRI; the results showed hyperintense signal alterations
in T2-weighted sequences and restricted diffusion in
diffusion weighted imaging (DWI) sequences in the an-
terior portion of the cervical and dorsal spinal cord, sug-
gesting anterior spinal artery territory involvement (Fig.
1b). Computed tomography angiography (CT) imaging
showed no arterial dissection or other vessel abnormal-
ities. Visual evoked potentials were normal. Somatosen-
sory evoked potentials in both legs showed decreased
conduction velocities. Motor evoked potentials showed
lower amplitude for cortical derivation, prolonged la-
tency in the upper limbs and normal in the lower limbs.
Central conduction time was increased in the upper
limbs and normal at the lower limbs. Complete auto-
immunity and thrombophilia screening were unremark-
able. Testing for anti-AQP4 antibodies was negative, and
anti-MOG antibodies were not significantly elevated. A
cardiologic consultation and echocardiography identified
normal heart and aorta features. At the ophthalmological
assessment, pupillary reactions were normal, the fundus
oculi did not reveal pathological signs, and color vision
was not affected. The visual acuity was 9/10 bilaterally.
The digital visual field test displayed a mild defect in the
peripheral portion of the visual field that was more evi-
dent in the left eye. Optical coherence tomography, vis-
ual evoked potential and electroretinograms were
normal. As the child grows, her visual function will
Table 1 Clinical findings at prolonged follow-up of the entire family. No family member presented signs of a spinal cord lesion or
pediatric onset of the symptoms. The individuals in the family pedigree are identified as follows: 1 Great-grandmother; 2, Uncle; 3,
Uncle; 4, Grandmother; 5, Aunt; 6, Aunt; 7, Mother; 8, Proband
1 Great
grandmother
2 Uncle 3 Uncle 4 Grandmother 5 Aunt 6 Aunt 7 Mother 8 Proband
Gender F M F F F F F F
Mutation
G3460A
Heteroplasmic Homoplasmic Homoplasmic Homoplasmic Homoplasmic Homoplasmic Heteroplasmic Homoplasmic
Age at
onset -y
Unknown Unknown Unknown 30 21 9 – 5
Signs of
onset
Ipovisus Ipovisus Iipovisus Ipovisus
Unilateral to
bilateral optic
neuritis
Ipovisus
Unilateral
optic neuritis
Ipovisus
Bilateral optic
neuritis
No signs at
ophthalmologic
visit 2011
Spinal cord
lesion
MRI brain
signs
– – – Multiple
periventricular
subcortical lesion
– – – Negative
OCB in CSF – – – Absent – – – Absent
Progression
of the
disease
Blindness Blindness
Headache
Blindness
Psychiatric
comorbidities
Vertigo
Tremor
Diplopia
Psychiatric trait
Bilateral
scotoma
Headache
Monolateral
scotoma left eye;
blind right eye
– –
Disorders
associated
Unknown Unknown Unknown Rolandic epilepsy
Pericarditis
ANA pos.
Osteoid
osteoma
LLAC pos.
Connectivitis
Headache Cutaneous
mastocytosis
Therapy Idebenon – Aspirin
Corticosteroids
Idebenon
Follow-up
duration
20 ys 20 ys 20 ys 20 ys 7 ys 14 ys 5y 1 y
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require careful monitoring, particularly when she
reaches the adolescence.
After obtaining written informed consent consistent
with the principles set forth in the Declaration of Helsinki,
total DNA was isolated from the patient’s peripheral blood
according to standard protocols. Full-length mitochon-
drial DNA sequencing was conducted according to a pre-
viously described protocol [4], and detected the
haplogroup H27 was detected in the proband. The follow-
ing variants were detected in the homoplasmic state:
m.41C > T, m.73A >G, m.263A >G, m.1438A >G,
m.3460G >A, m.4769A >G, m.8860A >G, m.11719G > A,
m.15326A >G, m.16129G >A, m.16316A >G, m.16519
T > C. Based on the presence of the m.11719G >A and
m.16316A >G nucleotide variants, the patient is predicted
to belong to the H27 haplogroup. The m.3460G > A tran-
sition, a major mutation associated with LHON, was veri-
fied in blood-derived DNA of other family members by
PCR-RFLP analysis.
Acetylsalicylic acid was administered at low doses (2.5
mg/kg daily), and high doses of methylprednisolone (20
mg/kg daily) were empirically administered for three
days. Although no proven treatments for LHON are
available, early treatment with idebenone is thought to
limit the progression of the disease; the patient was ad-
ministered 45mg of idebenone three times daily. Within
two days following this therapy, clinical manifestations
improved, and the patient regained bladder control and
Fig. 1 Family pedigree and MRI spinal cord imaging. a. Family pedigree; the patient is number 8. b. Spinal cord MRI T2-weighted/DWI sequences
indicating a hyperintense cervical-dorsal lesion. c. Spinal cord MRI T2-weighted/DWI sequences obtained 10 days later, showing regression of the
hyperintense signal
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the ability to ambulate; within one week, the girl also re-
covered nearly normal strength in both arms. A control
spinal cord MRI together with 1H-MRS to study the lac-
tate peak was performed 10 days after hospital admission;
the results showed complete regression of the alterations
and no abnormal metabolites (Fig. 1c). The patient contin-
ued outpatient rehabilitation, and her motor functions im-
proved, resulting in an almost completely normalized
neurological examination after 2months and preserving
these achievements at follow-up one year later.
Discussion
In the case described here, the acute onset associated
with back pain and the spinal cord MRI alteration in the
region of the anterior spinal cord artery could first sug-
gest an arterial infarction. Indeed, LHON can be associ-
ated with cardiac arrhythmias and can predispose
individuals to embolic events [5]. The patient’s symp-
toms improved rapidly after corticosteroid treatment,
and there was a significant reduction of the signal in the
spinal cord MRI ten days later, a pattern more consistent
with an inflammatory origin of the lesions. A condition
characterized by MS-like neuropathological and clinical
findings in the presence of an LHON mtDNA mutation
was described by Harding and referred to as “Harding
disease” or “LHON-MS”. LHON-MS is characterized by
recurrent episodes of visual loss associated with ocular
pain and central nervous system demyelination along
with unmatched cerebrospinal fluid oligoclonal bands. In
past years, authors have extensively discussed the possi-
bility that LHON-MS syndrome could be coincidental;
an interesting point addressed in these discussions was
whether and how the two diseases reciprocally influence
their natural histories [6]. Upregulation of mitochondrial
manganese superoxide dismutase and increased expres-
sion of inducible nitric oxide synthase within the inflam-
matory lesions have been described.
The 3460G >A mtDNA mutation occurs in the ND1
gene, which encodes a subunit of complex-I of the electron
transport chain, NADH: ubiquinone oxidoreductase; the
mutation reduces the rotenone- and ubiquinone-dependent
electron transfer activity of complex without affecting the
activity of proximal NADH dehydrogenase [7]. We specu-
late that the energy imbalance produced by this genetic de-
fect could lead to the spinal cord manifestations seen in
this patient due to the high energetic demand of the spinal
cord anterior horn. In some mitochondrial diseases (e.g.,
MELAS), stroke-like lesions in the brain are the conse-
quence of an energy imbalance between the demand for
and the availability of ATP in neurons, astrocytes and endo-
thelial cells [3]. Some MELAS/LHON cases have been re-
ported, but none of these cases had spinal cord
involvement. Some authors have suggested that the mito-
chondrial dysfunction acts as a driver of neurodegeneration
both in the classic LHON presentation and in the MS-like
pathology through energy deficiency, hypoxic-like tissue in-
jury and exposure of mtDNA-encoded proteins as histo-
compatibility antigens [1, 8]. A progressive metabolic
axonopathy was reported by Jaros [9] in a case of LHON as
a result of a lifelong pathology, and no evidence of demye-
lination was observed in the autoptic spinal cord; it has
been speculated that different mtDNA mutations predis-
pose different neuronal types to specific susceptibility to
neurodegeneration [9–11]. Spinal cord involvement during
the onset of two cases of LHON mimicking neuromyelitis
optica has recently been described [12, 13], emphasizing
the necessity of better characterizingin its early stages. We
acknowledge the possibility that our patient might have
Fig. 2 Timeline
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co-occurrence of the LHON mutation and inflammatory
CNS pathology; indeed, it is possible that the two diseases
reciprocally influence each other’s natural history. How-
ever, neither the criteria of seronegative NMO nor the MS
clinical diagnostic criteria were fulfilled at one-year
follow-up [14, 15]. To our knowledge, this is the first re-
ported case of a pediatric spinal cord acute lesion that
could represent the onset of neurological manifestations
in a patient carrying a typical LHON mutation. Incom-
plete penetrance is not uncommon in LHON, and factors
including additional mtDNA variants [16] and mtDNA
haplogroups [17] have been proposed to influence the on-
set and progression of disease in patients with the LHON
mutation. Direct sequencing of full mtDNA in our case
ruled out a synergic role of other mtDNA mutations, and
no experimental data support a role of the predicted H27
haplogroup as a genetic modifier in LHON. We cannot
exclude the possibility that other factors, such as nuclear
background [18, 19], might be relevant to protecting our
patient from optic nerve pathology or might influence the
peculiar aspects of her clinical presentation.
Conclusions
A precise description of LHON patients presenting with
extraocular neurological symptoms appears fundamental
for clarifying the variability of different phenotypes and
presentations and tailoring the therapeutic intervention.
Early identification of new cases and monitoring of car-
riers beginning in childhood is important to prevent
neurological and ophthalmological deterioration and
preserve long-term function. Our case reports a novel
pediatric clinical manifestation associated with the
G3460A mtDNA mutation, broadening the clinical
spectrum of this disease.
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